Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Chatelut

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluationS Guichard, A Montazeri, E Chatelut, et al.
Cancer Chemotherapy and Pharmacology|July 8, 1998
Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in miceS Guichard, E Chatelut, I Lochon, et al.
Cancer Research|December 15, 1994
Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patientsL P Rivory, E Chatelut, P Canal, et al.
Anti-Cancer Drugs|September 23, 2000
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activityI Hennebelle, C Terret, E Chatelut, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 1, 1996
In vitro and in vivo protein binding of methotrexate assessed by microdialysisM B Maia, S Saivin, E Chatelut, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1997
How to predict carboplatin clearance from standard morphological and biological characteristics in obese patientsS Bénézet, R Guimbaud, E Chatelut, et al.
Journal of Pharmaceutical Sciences|May 1, 1989
A pharmacokinetic model for intraperitoneal administration of drugs: application to teniposide in humansP Canal, Y Plusquellec, E Chatelut, et al.
Bulletin Du Cancer|September 30, 1998
Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patientsL Martin, E Chatelut, A Boneu, et al.
Journal of Chromatography. A|November 24, 1995
Child cerebrospinal fluid analysis by capillary electrophoresis and laser-induced fluorescence detectionG Nouadje, H Rubie, E Chatelut, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancerE Chatelut, C Chevreau, V Brunner, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluationS Guichard, A Montazeri, E Chatelut, et al.
Cancer Chemotherapy and Pharmacology|July 8, 1998
Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in miceS Guichard, E Chatelut, I Lochon, et al.
Cancer Research|December 15, 1994
Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patientsL P Rivory, E Chatelut, P Canal, et al.
Anti-Cancer Drugs|September 23, 2000
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activityI Hennebelle, C Terret, E Chatelut, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 1, 1996
In vitro and in vivo protein binding of methotrexate assessed by microdialysisM B Maia, S Saivin, E Chatelut, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1997
How to predict carboplatin clearance from standard morphological and biological characteristics in obese patientsS Bénézet, R Guimbaud, E Chatelut, et al.
Journal of Pharmaceutical Sciences|May 1, 1989
A pharmacokinetic model for intraperitoneal administration of drugs: application to teniposide in humansP Canal, Y Plusquellec, E Chatelut, et al.
Bulletin Du Cancer|September 30, 1998
Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patientsL Martin, E Chatelut, A Boneu, et al.
Journal of Chromatography. A|November 24, 1995
Child cerebrospinal fluid analysis by capillary electrophoresis and laser-induced fluorescence detectionG Nouadje, H Rubie, E Chatelut, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancerE Chatelut, C Chevreau, V Brunner, et al.
Pageof 8